Data Readout

Genelux's OnPrime ovarian cancer trial slips again, pushing PFS data to late 2026

Genelux has pushed the OnPrime Phase 3 completion date three times since 2024, and the PFS readout for its oncolytic virus Olvi-Vec now depends on a trial still recruiting less than six months from its new target.

By AppliedXLJuly 13, 2026Trial NCT05281471

Executive Summary

Genelux's registrational Phase 3 trial of its oncolytic virus Olvi-Vec in platinum-resistant ovarian cancer is still recruiting patients as the sponsor's stated data window opens, with the trial's own completion date having moved later three separate times since 2024.
The trial's single primary endpoint measures progression-free survival against physician's choice chemotherapy plus bevacizumab in a population that has already exhausted at least three prior lines of therapy, a bar with no resolved oncolytic-virus precedent to weigh it against in this disease.
Genelux has now guided the same second-half-2026 window across three consecutive quarterly disclosures even as the underlying completion date has slipped, narrowing the gap between when the trial says it will finish and when the company has told investors to expect results.
No other trial identified shares Olvi-Vec's oncolytic-virus mechanism in this specific ovarian cancer population, leaving the readout as the field's own test of whether the approach can beat chemotherapy rather than a comparison against a rival's result.

The trial

OnPrime (NCT05281471) is a randomized, open-label Phase 3 study testing Olvi-Vec, an oncolytic virus given intraperitoneally, followed by platinum-doublet chemotherapy and bevacizumab, against physician's choice of chemotherapy plus bevacizumab in women with platinum-resistant or platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer. The trial enrolls patients who have already received at least three prior lines of systemic therapy, restricting the population to a heavily pretreated, late-line group. The single primary endpoint is progression-free survival by RECIST 1.1 in the intention-to-treat population, with overall survival, response rate, and duration of response tracked as secondary measures. NCT05281471

Probability of Success

Endpoint Met96%

Completes23%

Clinical Significance47%

Regulatory85%

The completion-date history

The trial's primary completion date has moved three times in the registry: from August 2024 to August 2025 in April 2024, from August 2025 to June 2026 in September 2025, and from June 2026 to December 2026 on July 10, 2026. Genelux's chief executive, Thomas Zindrick, told investors in the company's third-quarter 2025 disclosure that "given the complexities inherent to running rigorous, randomized studies that can enable streamlined regulatory review, we now expect data in the second half of 2026". The company has repeated that same second-half-2026 guidance across filings dated November 2025, March 2026, and May 2026, even as the underlying completion date kept slipping. NCT05281471+1

Enrollment, held flat

Enrollment has stayed at its 186-patient target with no reported increase or shortfall, which the trial's own operational-risk model flags as within the routine range. The trial remains listed as Recruiting as of July 2026, meaning it has not yet closed enrollment even as its completion date extends toward the same window Genelux has guided for topline data. Genelux's own disclosure describes enrollment as "active across U.S. sites" with engagement from investigators across the enrolling network. NCT05281471+1

The competitive frame

Among trials identified in platinum-resistant or platinum-refractory ovarian cancer, none shares Olvi-Vec's oncolytic-virus mechanism; the nearest comparators, including a TROP2-directed antibody-drug conjugate and an ATR inhibitor in the broader ovarian cancer landscape, work through unrelated mechanisms and are not direct comparators. Within oncolytic virotherapy more broadly, the closest analogs, Replimune's vusolimogene oderparepvec in cutaneous malignancies and a virotherapy program from Accession Therapeutics in tumors, sit in different indications and different viral targets. That leaves the OnPrime result as the field's own test of the mechanism in this disease, without a resolved same-mechanism outcome in ovarian cancer to benchmark against.

The regulatory backdrop

The FDA granted Olvi-Vec Fast Track designation for platinum-resistant/refractory ovarian cancer, which Genelux disclosed in November 2023, a signal of unmet need that allows more frequent FDA interaction but does not itself predict trial outcome. Genelux has described the trial as intended to support registration, and the sponsor's broader trial portfolio includes five completed studies and no terminations among its four resolved industry-sponsored trials.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.